Marie-Agnes Bernard
Overview
Explore the profile of Marie-Agnes Bernard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thurin N, Grelaud A, Grolleau A, Bernard M, Bignon E, Blin P, et al.
Pharmacoepidemiol Drug Saf
. 2024 Mar;
33(4):e5781.
PMID: 38527971
Purpose: This paper aims to introduce an algorithm designed to identify Venous Thromboembolism (VTE) in the French National Healthcare Database (SNDS) and to estimate its positive predictive value. Methods: A...
2.
Hurley E, Geisler B, Lupattelli A, Poblador-Plou B, Lassalle R, Jove J, et al.
Eur J Clin Pharmacol
. 2024 Feb;
80(5):707-716.
PMID: 38347228
Purpose: The COVID-19 pandemic has impacted medication needs and prescribing practices, including those affecting pregnant women. Our goal was to investigate patterns of medication use among pregnant women with COVID-19,...
3.
Blin P, Joubert M, Jourdain P, Zaoui P, Guiard E, Sakr D, et al.
Cardiovasc Diabetol
. 2024 Jan;
23(1):22.
PMID: 38195491
Background: Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes. The objective...
4.
Blin P, Darmon P, Henry P, Guiard E, Bernard M, Dureau-Pournin C, et al.
Cardiovasc Diabetol
. 2021 Nov;
20(1):229.
PMID: 34823531
Aim And Hypotheses: The THEMIS randomized trial compared ticagrelor plus aspirin versus placebo plus aspirin for patients with stable coronary artery disease and type 2 diabetes mellitus (CAD-T2DM), and without...
5.
Bosco-Levy P, Grelaud A, Blin P, Astruc B, Falissard B, Llorca P, et al.
Pharmacoepidemiol Drug Saf
. 2020 Aug;
30(2):169-177.
PMID: 32767421
Purpose: To estimate annual incidence and prevalence of Treatment-Resistant Depression (TRD) in France. Methods: We identified all adult patients (≥ 18 years) with a TRD episode between 1 January 2012...
6.
Fauchier L, Blin P, Sacher F, Dureau-Pournin C, Bernard M, Lassalle R, et al.
Europace
. 2019 Oct;
22(2):205-215.
PMID: 31638652
Aims: The real-life benefits and risks of the non-vitamin K antagonist oral anticoagulants for stroke prevention in very elderly patients with atrial fibrillation (AF) are still debated. Methods And Results:...
7.
Blin P, Fauchier L, Dureau-Pournin C, Sacher F, Dallongeville J, Bernard M, et al.
Stroke
. 2019 Aug;
50(9):2469-2476.
PMID: 31390972
Background and Purpose- We compared the 1-year safety and effectiveness of rivaroxaban 15 mg (R15) or rivaroxaban 20 mg (R20) to vitamin K antagonists (VKAs) in patients with nonvalvular atrial...
8.
Droz-Perroteau C, Blin P, Dureau-Pournin C, Thomas D, Danchin N, Tricoire J, et al.
Therapie
. 2019 Mar;
74(4):459-468.
PMID: 30878144
Background: Studies of survival after myocardial infarction (MI) are often based on intention to treat analyses of controlled trials. Objectives: Describe long-term survival after MI in France. Methods: Six-year cohort...
9.
Gouverneur A, Coutureau J, Jove J, Rouyer M, Grelaud A, Duc S, et al.
Clin Colorectal Cancer
. 2019 Jan;
18(1):e150-e162.
PMID: 30630730
Background: Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Their real-life evaluation is insufficient, especially in elderly and frail patients. The aim was to describe use, safety, and...
10.
Noize P, Grelaud A, Bay J, Chevreau C, Gross-Goupil M, Culine S, et al.
Pharmacoepidemiol Drug Saf
. 2017 Jun;
26(12):1561-1569.
PMID: 28573786
Purpose: To investigate sunitinib in the real-life first-line treatment of metastatic renal cell carcinoma (mRCC). Methods: SANTORIN is a French observational multicentre cohort. Patients initiating sunitinib in first-line mRCC therapy...